Article info
Clinical and epidemiological research
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
- R Fleischmann, University of Texas Southwestern Medical Center, 5939 Harry Hines Blvd., Dallas, Texas 75235, USA; rfleischmann{at}arthdocs.com
Citation
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
Publication history
- Accepted October 29, 2008
- First published November 17, 2008.
Online issue publication
May 12, 2009
Article Versions
- Previous version (17 November 2008).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Fleischmann et al 2009 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.